Literature DB >> 22312374

The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats.

Xiwen Gao1, Yi Huang, Yipin Han, Chun-Xue Bai, Guifang Wang.   

Abstract

INTRODUCTION: To evaluate the effect of pan class="Chemical">Ambroxol on the pulmonary surfactant (PS) in rat pneumonia induced by Pseudomonas aeruginosa (PA).
MATERIAL AND METHODS: The pneumonic rats were obtained by injecting ATCC27853 intratracheally. One hundred and twenty SD rats were randomized into four groups: normal saline and Ambroxol was injected intraperitoneally following PA challenge in the PA/NS and PA/AM group; the other two groups were NS/AM and NS/NS. The wet/dry weight ratio (W/D), and pathological changes were assayed. Total proteins (TP), total phospholipid (TPL), and dipalmitoylphosphatidylcholine (DPPC) in bronchial alveolar lavage fluid (BALF) were analysed. Some BALF was cultured for colony counts. Ultrastructural change of the lung was observed by electron microscopy.
RESULTS: The W/D ratio in the PA/AM group was lower than that in the PA/NS group; both were higher than that in the NS/NS group (p < 0.05). There were more neutrophils in the PA/NS group than in the PA/AM group (p < 0.05), and more in the PA/AM group than in the NS/NS group (p < 0.05). The ratio of DSPC/TPL and DSPC/TP in the BALF in PA/NS group was lower than that in the PA/AM group; DSPC/TPL and DSPC/TP ratios also increased in the NS/AM group. The PA colony numbers in the PA/AM group were lower than in the PA/NS group (p > 0.05). In the PA/NS group, vacuolation occurred in the lamellar body of alveolar type 2 cells (AT2) and the PS layer was rough and broken in some areas. In the PA/AM group, the degree of vacuolation of the lamellar body was less than in the PA/NS group.
CONCLUSIONS: Ambroxol could protect rats from pneumonia by improving the level of endogenous PS, especially DPPC.

Entities:  

Keywords:  Ambroxol; Pseudomonas aeruginosa; bronchoalveolar lavage; pneumonia; pulmonary surfactant

Year:  2011        PMID: 22312374      PMCID: PMC3258752          DOI: 10.5114/aoms.2011.23403

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

Pseudomonas aeruginosa (pan class="Species">PA) is the one of the most common pathogens involved in nosocomial pneumonia and is responsible for both high mortality and morbidity in critically ill patients [1]. Presently, treatment for this disorder consists primarily of antibiotic administration, but typical antibiotic combinations have little effect on patient morbidity and mortality with the rising resistance rate to many drugs [2, 3]. This is derived from its multiple mechanisms of innate and acquired resistant-antibiotics [4-6], especially developing drug-induced resistance. Therefore other methods apart from antibiotics should be investigated to manage this disorder. Studies on bronchoalveolar lavage fluid (BALF) obtained from patients with both Gram-positive and -negative pan class="Disease">pneumonia have demonstrated alterations in the endogenous surfactant system [7-9]. This is partially due to the degradation of bacterial content to the surfactant, for example, the combination of phospholipase C and lipase from PA was reported to result in degradation of dipalmitoylphosphatidylcholine (DPPC), producing palmitic acid and dipalmitoylglycerol, though lipase alone produced no degradation [10]. Further evidence suggests that surfactant may play a role in the lung dysfunction associated with pneumonia stems from the observed surfactant alterations in patients with acute respiratory distress syndrome (ARDS), which is associated with similar alterations in lung mechanics and the surfactant system. Some studies have shown that these changes contribute to the lung dysfunction observed in ARDS and exogenous surfactant has shown promise as a therapeutic modality in these patients and animal models such as rabbits and rats [11-14]. But, the elements of exogenous pulmonary surfactant are different from one another; for example, Exosurf is a synthetic pulmonary surfactant [15], Survanta is a natural bovine surfactant extract (including pan class="Gene">SP-B, SP-C, not SP-A) [15], Curosurf is a porcine surfactant extract (SP-B, SP-C) [16]. Therefore there have been some difficulties to contrast the efficacy between any two medications and set up a standard formula of PS administration. But Ambroxol, a mucolytic agent, exhibits not only antioxidant and anti-inflammatory properties with reduction of the release of inflammatory cytokines from bronchoalveolar macrophages, monocytes and granulocytes [17], but also, it is found to increase alveolar type II cell (AT2)-secreted surfactant proteins [18]. Therefore if used as the actor of a surfactant, it can be administered easily and contrasted the efficacy. There is now ample evidence that Ambroxol is a very potent inducer of surfactant synthesis in young and adult organisms and in alveolar type II cells from different animals [19]. This study was performed to use Ambroxol for treating pneumonia induced by PA and to provide some support for further clinical use.

Material and methods

Materials

Animals

Protocols for animal care and experimental management were approved by the Fudan University’s Scientific Committee. Healthy adult SD rats (~220-240 g) were anaesthetized with 1% sodium pentobarbital intraperitoneally at a dose of 50 mg/kg.

Bacteria

ATCC27853 is a standard line of pan class="Species">PA obtained from ATCC. Pseudomonas aeruginosa cultured in broth for 18 h were diluted to 2 McFarland with normal saline (6 × 108 CFU/ml, 1 McFarland = 3 × 108 CFU/ml).

Drug for treatment

Ambroxol hydrochloride injection (MucosolvanR) (Boehringer Ingelheim Co. Ltd, China), 7.5 mg/ml. Normal saline was used as the control of pan class="Chemical">Ambroxol.

Methods

Animal experiment procedure

One hundred and twenty rats were divided randomly into four groups, 30 pan class="Species">rats in each group : PA/NS group, PA/AM group, NS/AM group, NS/NS group. The rats in the PA/NS group and PA/AM group were anaesthetized with sodium pentobarbital (50 mg/kg) administered intraperitoneally. This study had two stages which contained animal infected PA and the treatment of infection. After the trachea was exposed by blunt dissection and tracheal annulations, all of them were instilled with 0.2 ml P. aeruginosa suspension intratracheally followed by an injection of 0.5 ml of air (2 McFarland units of ATCC27853 suspension obtained according to the former methods) to copy the pneumonia of rat models. After 6 h, these rats were administered normal saline (the volume of NS was 0.6 ml, which was equal to the volume of used Ambroxol) and Ambroxol (20 mg/kg) through the vena caudalis. Both the NS/AM group and NS/NS group were given NS (0.2 ml) intratracheally. Six h later, the rats in the NS/AM group received Ambroxol (20 mg/kg) and in the NS/NS group received normal saline 0.6 ml via a 28 G catheter respectively. Four groups were allowed to recover and ad liter.

Samples procedure

After 6 h, samples were obtained according to the research aims. Most of them were referred as follows. Wet-to-dry lung weight measurements After the rats had been sacrificed, an incision was made in the abdominal wall and the chest was then opened. In each group (five animals), a piece of lung tissue (about 2 g) from the back side of the left lower lobe was cut and the wet weight was determined in an automatic electric balance (AP250D; Ohaus, Florham, NJ). All pieces of lung tissue were then stored at 70°C for 72 h and weighed again to obtain their dry weight for calculating the wet-to-dry weight pan class="Species">ratio (W/D). In another four animals in each group both lungs were fixed by vascular perfusion for histological analysis. The pulmonary vessels were lavaged with normal saline via right ventricular. The rat lungs were fixed at the pressure of 20 cm pan class="Chemical">H2O by intratracheal injection of a solution containing 2% glutaraldehyde and 1% paraformaldehyde in a 0.1 M phosphate buffer solution. The lungs were then prepared for sectioning using standard techniques. Sections were stained with haematoxylin-eosin. Polymorphonuclear cells (PMN) were counted on each slide by a pathologist not knowing the experiment project and repeated three times. BALF The volume of normal saline each animal needed was counted according to the dose of 40 ml/kg. Each rat needed 8.8-10.6 ml and was lavaged according to the pan class="Species">ratio of 4 : 3 : 3 three times. More than 85% of the instilled liquid was collected from each rat, and collected BALF was pooled and its total volume was recorded. Total 0.1 ml BALF was serially diluted and spread on blood agar plates for calculation of viable colony-forming units (CFU) of PA. After culture for 24 h at 37°C, all CFU were counted. All other BALF was immediately centrifuged for 3000 rpm lasting for 10 min to remove the cell debris, the supernatant was stored at –20°C for biochemical analysis. Samples for EM processed: all procedures for samples are described in the supplementary materials. Chemical analysis of bronchoalveolar lavage fluid and total protein All analysis methods are presented in Appendixes 1 and 2.

Statistical analysis

Statistics were conducted using SPSS software (SPSS, Chicago, IL) and the results are presented as means ± SD. One-way analysis of variance (ANOVA) procedures and post hoc analysis (LSD, significance level set at p < 0.05) were used for multiple comparisons.

Results

The appearance of rats inoculated with PA intratracheally and the weight ratio of wet/dry of the rat lungs of each group

After being inoculated with PA intpan class="Species">ratracheally from one to 3 h, all rats in both the PA/NS group and PA/AM group showed trembling, cyanosis, and some blood-tinged foams out of mouths and noses. All these rats breathed faster than before. Even one or two rats twitched with their hair being wet. Six h after being injected with Ambroxol, the rats in the PA/NS group acted just like before, but animals in the PA/AM group calmed down gradually. All animals administered NS and Ambroxol respectively in the first stage, which were referred to NS/AM and pan class="Disease">NS/NS groups, did not show uncomfortable appearance. To assay the water in the lungs of each group, the wet/dry weight ratio (W/D) was calculated. It was found that lung W/D increased significantly in the PA/NS group, which was 8.58 ±0.39. This ratio (7.47 ±0.22) in the PA/AM group was lower than that in the PA/NS group (p < 0.05), but both of them were significantly higher than that in both NS/AM and NS/NS groups. There was no statistical difference between NS/AM and NS/NS groups (Figure 1).
Figure 1

Wet/dry ratio of the lung of each group: wet/dry ratio of lung in PA/NS group was higher than that in PA/AM group (p < 0.05); both were higher than that in NS/AM and NS/NS group (p < 0.01), #NS/AM and NS/NS group (p < 0.05) and PA /AM group (p < 0.05), *any other group (p < 0.05)

Pathological appearance

Macropathologically, the lungs weighed and enlarged in all of the PA-challenged pan class="Species">rats (PA/NS, PA/AM group) much more than in NSor AM-challenged ones (NS/AM, NS/NS groups). The surfaces of the lungs from the PA-challenged rats were roughened with some purulent spots or pustules whose diameters were about 1-3 mm. The lungs of the PA/NS group were cut into several pieces; pink fluid was squeezed. The pulmonary pathological changes showed a decreasing trend of severity from the PA/NS to PA/AM group, while the lungs from the rats of the NS/AM and NS/NS group showed no changes. Pulmonary pathological study revealed striking contrasts between the PA/NS group and the pan class="Species">PA/AM group. In the lung of rats from the PA/NS group, there was bronchial mucosal epithelial cell exfoliation, hyperaemia and oedema seen in the bronchial submucosal layer with inflammatory cell infiltration, most of which were neutrophils, a few lymphocytes and macrophages. The alveolar walls were thickened with telangiectasia and congestive capillaries. A large amount of neutrophils and erythrocytes filled in the alveoli in areas that developed pustules. Alveolar septa ruptured in some portions of the lung due to compensatory alveolar ectasia. Compared with the PA/NS group, alveolar telangiectasia and congestive capillaries in the PA/AM group attenuated, where a scanty oedema fluid and lymphocytes were scattered in the alveolar cavities. Although some neutrophils and macrophages were found, they were far fewer than those in the PA/NS group. There were few inflammatory cells infiltrated in the lungs from both the NS/NS group and AM/NS group, with regular alveolar cavities. The inflammation of the lungs in each group was consistent with the semi-quantitative results. The neutrophils in high power were seen as a sign of inflammatory reaction. The inflammatory reaction in the pan class="Species">PA/NS group was slightly more prominent than that in the PA/AM group, but the latter was considerably less than that in the NS/NS and AM/NS group. The PMN number per high field in the PA/NS group was 111.4 ±14.8, in the PA/AM group 38.8 ±3.1, in the NS/AM group 6.0 ±4.4, and in the NS/NS group 4.4 ±2.6. There was a significant difference between the PA/NS group and all the other groups (p < 0.05, Figure 2). The other corresponding groups had no significant difference.
Figure 2

Semi-quantitative analysis of PMNs per high power field under the light microscope. After pathological slides were prepared, analysis of PMN was performed by a pathologist not knowing the experiment project. PMN numbers per high power field in PA/NS group were 111.4 ±14.8, in PA/AM group 38.8 ±3.1, in NS/AM group 6.0 ±4.4, and in NS/NS group 4.4 ±2.6. There was a significant difference between PA/NS group and all other groups *vs. NS/NS group (p < 0.05), #vs. PA/AM group (p < 0.05)

Analysis of the pulmonary surfactant in BALF of each group

Total protein in BALF was assayed from each group and it was found that there was higher concentration in the pan class="Species">PA/NS group (87.0 ±8.9 mg/kg). Ambroxol reduced TP in BALF in the PA/AM group, in which it was 81.4 ±7.8 mg/kg, TP in NS/AM group was 39.4 ±8.6 mg/kg, and in the NS/NS group was 36.6 ±6.1 mg/kg (Figure 3, p < 0.05, among any two groups but not for NS/AM group).
Figure 3

Total protein (TP) in BALF from lungs in each group. TP in PA/NS group was higher than that in NS/NS group (87.0 ±8.9 mg/kg and 36.6 ±6.1 mg/kg respectively, p < 0.05), both were higher than that in NS/AM and NS/NS group (p < 0.01), *vs. NS/NS group (p < 0.05)

The level of DPPC/pan class="Chemical">TPL and DPPC/TP in the PA/NS group was 38.6 ±11.0% and 19.1 ±6.9 µg/mg respectively, which was lower than that in the NS/NS group (49.6 ±5.4% and 59.8 ±14.7 µg/mg respectively) (p < 0.05). However, TP in BALF in the PA/NS group was higher than that in the NS/NS group with no change of concentration of TPL appearing in the PA/NS group. And there was no significant difference of TPL between any two groups (4.6 ±1.7 mg/kg for PA/NS group, 4.7 ±0.5 mg/kg for PA/AM group, 4.1 ±1.5 mg/kg for NS/AM group and 4.4 ±1.1 mg/kg for NS/NS group respectively, p > 0.05 for all) (Figure 4).
Figure 4

Analysis of contents of BALF in lungs from each group. Level of DPPC/TPL and DPPC/TP in PA/AM group elevated significantly compared to PA/NS group (65.7 ±7.8% and 38.6 ±11.0% respectively, p < 0.05). Concentration of DPPC/TP in BALF in PA/AM group elevated more than that in PA/NS group (38.6 ±10.2 µg/mg and 19.1 ±6.9 µg/mg respectively, p < 0.05). DPPC/TPL concentration in NS/AM group was higher than that in NS/NS group (68.3 ±8.4% and 38.6 ±11.0% respectively, p < 0.05), with the level of DPPC/TP in NS/AM group being higher than that in NS/NS group

The level of DPPC/pan class="Chemical">TPL and DPPC/TP in the PA/AM group elevated significantly compared to the PA/NS group (65.7 ±7.8% and 38.6 ±11.0% respectively, p < 0.05). The concentration of DPPC/TP in BALF in the PA/AM group elevated more than that in the PA/NS group (38.6 ±10.2 µg/mg and 19.1 ±6.9 µg/mg respectively, p < 0.05), but there was no change in the concentration of TP and TPL (Figure 4). And also, it was found that DPPC/pan class="Chemical">TPL concentration in the NS/AM group was higher than that in the NS/NS group (68.3 ±8.4% and 38.6 ±11.0% respectively, p < 0.05), with the level of DPPC/TP in the NS/AM group being higher than that in the NS/NS group, which may indicate that Ambroxol could increase the biosynthesis of PS in the normal rat lung (Figure 4).

Colony of bacteria in BALF of each group

There were no bacteria growing in media from BALF of both NS/AM and NS/NS groups. And there were many bacteria growing in media from BALF of both pan class="Species">PA/NS and PA/AM groups, which were identified as PA, whose biological features were just like the bacteria inoculated intratracheally. There were 10.35 ±2.10 (104 CFU/ml) and 8.02 ±3.2 (104 CFU/ml) respectively in PA/NS and PA/AM groups, but there was no statistical difference between the two groups (p > 0.05) (Figures 5 A-C).
Figure 5

Lung histology. Sections of lungs were prepared 6 h after being treated with NS and AM (A – PA/NS group, B– PA/AM group, C– NS/NS group. Original magnifications: ×200).These sections are representative of 5 to 10 different animals per group

Performance of lungs under electron microscopy

The normal ultramicrostructure of the lamellar body in alveolar type II cells (pan class="Chemical">AT2) and tubular myelin (TM) for exocytosis being intruded into the alveolar cavity could be found in both NS/NS and NS/AM groups (Figure 6 E). The PS layer on the surface of alveoli was homogeneous in both groups (Figure 6 F). But in the PA/NS group, vacuolation occurred in the lamellar body of AT2. The lattice and other types of tubular myelin exfoliated into the alveolar cavity (Figures 6 A, B). The PS layer was rough and was broken in some areas. In the PA/AM group, the degree of vacuolation of the lamellar body had more tendency to recovery than those in the PA/NS group and the PS layer was more perfectly distributed than the PA/NS group (Figures 6 C, D).
Figure 6

Electron microscopy. Sections of lungs were prepared 6 h after being treated with NS and AM and the procedure was according to the supplementary materials online. Normal ultramicrostructure of lamellar body in alveolar type II cells (AT2) and tubular myelin (TM) for exocytosis being intruded into alveolar cavity all could be found in both NS/NS and NS/AM group (E). The PS layer on the surface of alveoli was uniform in these two groups (F). But in PA/NS group, vacuolation occurred in lamellar body of AT2. Lattice and other types of tubular myelin exfoliated into the alveolar cavity (A, B). PS layer was rough and was broken in some areas. In PA/AM group, degree of vacuolation of lamellar bodies had more tendency to recovery than those in PA/NS group and PS layer was more perfectly distributed than PA/NS group (C, D)

Discussion

Here, by injecting PA pan class="Chemical">ATCC27853 intratracheally, rat pneumonia models were produced. After being inoculated for 3 h, all rats challenged with PA showed trembling, dyspnoea and hair-wet. The pathological lungs weighed and enlarged in all of the PA-challenged rats. Lung surfaces were rough with some purulent spots or pustules. A pink water-like fluid flowed from its cut cross-sectional surface when squeezed. And also the lungs from the rats challenged with PA showed higher W/D ratio than that with NS and Ambroxol. More than that, PA were cultured from BALF obtained from rats challenged with PA, and their biological features were identical to the inoculated ones. Under light microscopy, inflammatory cells infiltrated the lungs and most of them were neutrophils. All this indicated that the pneumonia models succeeded. To assay the BALF content, it was found that TP in BALF from rats in the pan class="Species">PA/NS group increased, while DPPC/TPL, DPPC/TP decreased, which may indicate that DPPC in PS was relatively lowered. This work presented results just like those obtained by Wanderzwan et al. [23]; they found that the content of TPL, DPPC and large surfactant aggregates (LSA) decreased. Together these assays of the level of DPPC/TPL, DPPC/TP in BALF in severe pneumonia could suggest the prognosis of pneumonia. Now it is suggested that phospholipase secreted by bacteria may play some role to decrease PS in bacterial pneumonia. Lema et al. [24] found the pan class="Species">calf lung surfactant extract hydrolysis was catalyzed by extracts (mostly phospholipase C) of the PA, particularly the non-mucoid types, which severely affected surfactant function. And they concluded that this mechanism might be the most important injury factor. Here in our study the lung in the PA/NS group under electron microscopy presented that PS liner ruptured and twisted, and even dropped into the alveolar cavities, which indicated that some conconts of PA injured the PS liner. If being given Ambroxol, the extent of injury lessened. It is well known that the PS is synthesized and secreted by AT2, most of which consists of pan class="Chemical">phospholipids (PL) and up to 80% to 85%, mainly dipalmitoylated phosphatidylcholine (DPPC) and phosphatidylglyceride (PG), and acts to maintain alveolar stability. And also, PS, especially PL, can modulate the inflammatory reaction of normal and abnormal lungs, and even has bacteria-inhibiting effects [12, 25]. Among all contents of PS, SP-D plays a more important role than any other. There were some results about human pneumonia that showed decreased SP-A in patients with bacterial pneumonia [26]. From the results, it could be found that there was a large amount of infiltration in the alveolar cavity, increased W/D ratio, and also TP rise, and lower DPPC/TPL and DPPC/TP. All these combined together may indicate the deficiency or impairment of the PS layer, and this gave evidence of exogenous PS replacement. Some researchers [27] found that a large amount (~300-500 mg/kg b.w.) by intrabronscopic administration in septic shock patients caused far-reaching restoration of biochemical surfactant properties and significant improvement. With this method, gas-exchange ability rose significantly. And Protsiuk [28] used exogenous PS associated with antibiotics to treat pneumonia in children and found that the effect of two methods was much better than that of only antibiotics. Now, Ambroxol has been used for many years all over the world to manage respiratory tract disorders. This compound was originally developed as a mucolytic agent [29], but it was soon discovered that it influences the secretory apparatus of the bronchial epithelium and pulmonary alveoli. There is now ample evidence that Ambroxol is a very potent inducer of surfactant synthesis in young and adult organisms and in alveolar type II cells from different animal species [30]. The mechanism has not yet been understood completely. Von Vichert et al. [31] reported that Ambroxol in healthy rabbits increases the phospholipid content of the lung. This study also proved by EM that Ambroxol could promote the function of PS. In pan class="Species">rats from PA/NS group, it was found that vacuolation occurred in the lamellar body in AT2. The lattice and other types of tubular myelin exfoliated into the alveolar cavity. The PS layer was rough and was broken in some areas. In the PA/AM group, the degree of vacuolation of the lamellar body had more tendency to recovery than those in the PA/NS group and the PS layer was more perfectly distributed in the AT2 than that in the PA/NS group, and few lamellar bodies exfoliated. This result indicated that after AT2 were stimulated, the synthesis and secretion of PS also increased. Another study indicated that Ambroxol can help to increase the local concentration of antibiotics and reduce the morbidity of infectious diseases [32, 33]. In our work, though there was no statistical difference regarding the amount of bacteria’s CFU between the PA/NS group and PA/AM group (p > 0.05), the inflammatory infiltration of lungs in the PA/AM group was less than that in the PA/NS group. Yang et al. [34] suggested that Ambroxol protected mice challenged with influenza virus from lethal effects and improved the mice survival rate partly through inhibiting the releasing of cytokines such as TNF-α, IFN-γ and IL-12, and promoting the secretion of the release of suppressors of influenza virus multiplication, such as pulmonary surfactant (mostly SP-A, rising 1.5-1.7 fold), immunoglobulin (Ig)-A and IgG, etc. Therefore it may be that Ambroxol could stimulate the synthesis and secretion of exogenous PS in lungs of infected rats and exert a protective effect. Further, analysis of BALF of non-infected rats suggested that this stimulation was not limited to infected rats, which meant in normal rat lungs Ambroxol acted in the same role. Now, exogenous PS is very expensive and there is no standard about this drug. But all packages of Ambroxol are relatively economical and the usage is relatively simple, so it perhaps acts on the responsibility and aids in severe or resistant lung infection. The definite mechanism of this drug might need to be investigated.
  27 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant.

Authors:  G Lema; D Dryja; I Vargas; G Enhorning
Journal:  Pediatr Res       Date:  2000-01       Impact factor: 3.756

3.  Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia.

Authors:  R Schmidt; U Meier; M Yabut-Perez; D Walmrath; F Grimminger; W Seeger; A Günther
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

4.  Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms.

Authors:  Richard J Gillis; Kimberly G White; Kyoung-Hee Choi; Victoria E Wagner; Herbert P Schweizer; Barbara H Iglewski
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Cell-specific modulation of surfactant proteins by ambroxol treatment.

Authors:  Carola Seifart; Ursula Clostermann; Ulf Seifart; Bernd Müller; Claus Vogelmeier; Peter von Wichert; Heinz Fehrenbach
Journal:  Toxicol Appl Pharmacol       Date:  2005-02-15       Impact factor: 4.219

6.  Surfactant treatment in experimental Escherichia coli pneumonia.

Authors:  G W Song; B Robertson; T Curstedt; X Z Gan; W X Huang
Journal:  Acta Anaesthesiol Scand       Date:  1996-10       Impact factor: 2.105

7.  Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome.

Authors:  G F Zhu; B Sun; S F Niu; Y Y Cai; K Lin; R Lindwall; B Robertson
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

8.  Decreased surfactant protein A in patients with bacterial pneumonia.

Authors:  R P Baughman; R I Sternberg; W Hull; J A Buchsbaum; J Whitsett
Journal:  Am Rev Respir Dis       Date:  1993-03

9.  Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.

Authors:  S S Sehgal; C K Ewing; T Richards; H W Taeusch
Journal:  J Natl Med Assoc       Date:  1994-01       Impact factor: 1.798

10.  Extracellular lipase of Pseudomonas aeruginosa: biochemical characterization and effect on human neutrophil and monocyte function in vitro.

Authors:  K E Jaeger; A Kharazmi; N Høiby
Journal:  Microb Pathog       Date:  1991-03       Impact factor: 3.738

View more
  4 in total

1.  Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats.

Authors:  Shohei Kanie; Masanao Yokohira; Keiko Yamakawa; Yuko Nakano-Narusawa; Shota Yoshida; Nozomi Hashimoto; Katsumi Imaida
Journal:  J Toxicol Pathol       Date:  2016-12-22       Impact factor: 1.628

Review 2.  Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?

Authors:  Markus Depfenhart; Danielle de Villiers; Gottfried Lemperle; Markus Meyer; Salvatore Di Somma
Journal:  Intern Emerg Med       Date:  2020-05-26       Impact factor: 3.397

3.  Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents.

Authors:  Shota Yoshida; Masanao Yokohira; Keiko Yamakawa; Yuko Nakano-Narusawa; Shohei Kanie; Nozomi Hashimoto; Katsumi Imaida
Journal:  J Toxicol Pathol       Date:  2018-06-09       Impact factor: 1.628

Review 4.  Characteristics of surfactant proteins in tumorigenic and inflammatory lung lesions in rodents.

Authors:  Masanao Yokohira; Keiko Yamakawa; Yuko Nakano-Narusawa; Nozomi Hashimoto; Shohei Kanie; Shota Yoshida; Katsumi Imaida
Journal:  J Toxicol Pathol       Date:  2018-06-02       Impact factor: 1.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.